Melanoma

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
Josep Malvehy, Igor Samoylenko, Dirk Schadendorf, Ralf Gutzmer, Jean-Jacques Grob, Joseph J Sacco, Kevin S Gorski, Abraham Anderson, Cheryl A Pickett, Kate Liu, Helen Gogas

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e001621; DOI: 10.1136/jitc-2020-001621
Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report
Khashayar Esfahani, Meagan-Helen Henderson Berg, Hanieh Zargham, Robin Billick, Kevin Pehr, Margaret Redpath, Osama Roshdy, Wilson H Miller

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e001831; DOI: 10.1136/jitc-2020-001831
When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report
Marie-Léa Gauci, Barouyr Baroudjian, Celeste Lebbe, Olivier Roux

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e002337; DOI: 10.1136/jitc-2021-002337
MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination
Xiaofang Wu, Marie Nelson, Mousumi Basu, Priya Srinivasan, Christopher Lazarski, Peng Zhang, Pan Zheng, Anthony David Sandler

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e001388; DOI: 10.1136/jitc-2020-001388
Human CD141⁺ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model
Yoke Seng Lee, Liam J O'Brien, Carina M Walpole, Frances E Pearson, Ingrid M Leal-Rojas, Kelly-Anne Masterman, Victoria Atkinson, Andrew Barbour, Kristen J Radford

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e001963; DOI: 10.1136/jitc-2020-001963
T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A⁺CD141⁺ cDC1 and CD14⁺ antigen-presenting cell recruitment
Bas D Koster, Marta López González, Mari FCM van den Hout, Annelies W Turksma, Berbel JR Sluijter, Barbara G Molenkamp, Paul AM van Leeuwen, Saskia Vosslamber, Rik J Scheper, Alfons JM van den Eertwegh, M Petrousjka van den Tol, Ekaterina J Jordanova, Tanja D de Gruijl

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e001962; DOI: 10.1136/jitc-2020-001962
Considerations for treatment duration in responders to immune checkpoint inhibitors
Thomas U Marron, Aideen E Ryan, Sangeetha M Reddy, Sabina Kaczanowska, Rania H Younis, Dipti Thakkar, Jiajia Zhang, Todd Bartkowiak, Rachel Howard, Kristin G Anderson, Daniel Olson, Abdul Rafeh Naqash, Ravi B Patel, Esha Sachdev, Maria E Rodriguez-Ruiz, Michal Sheffer, Sarah Church, Christopher Fuhrman, Abigail Overacre-Delgoffe, Rosa Nguyen, Vaia Florou, Jessica E Thaxton, David H Aggen, Jennifer L Guerriero

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e001901; DOI: 10.1136/jitc-2020-001901
TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism
Stefania Canè, Jacques Van Snick, Catherine Uyttenhove, Luc Pilotte, Benoit J Van den Eynde

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e001798; DOI: 10.1136/jitc-2020-001798
Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort
Xue Bai, Michelle Kim, Gyulnara Kasumova, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Justine Cohen, Donald Lawrence, Christine Freedman, Riley Fadden, Krista Rubin, Tatyana Sharova, Dennie Frederick, Keith Flaherty, Ryan Sullivan, Jun Guo, Genevieve Boland

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e002092; DOI: 10.1136/jitc-2020-002092
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Julia Maria Ressler, Matthias Karasek, Lukas Koch, Rita Silmbrod, Joanna Mangana, Sofiya Latifyan, Veronica Aedo-Lopez, Helmut Kehrer, Felix Weihsengruber, Peter Koelblinger, Christian Posch, Julian Kofler, Olivier Michielin, Erika Richtig, Christine Hafner, Christoph Hoeller

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e001701; DOI: 10.1136/jitc-2020-001701

Main menu

Melanoma

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Melanoma

Pages